Lederfolin (Folinic Acid)

Lederfolin is a folate analog used in clinical situations where folate metabolism is compromised or where antifolate drugs pose a toxicity risk.

• Rescue therapy after high‑dose methotrexate: restores folate‑dependent DNA synthesis and reduces methotrexate‑induced toxicity.
• Adjunct in cancer chemotherapy regimens: supports normal cell recovery during antifolate‑based treatment.
• Prevention of toxicity from antifolate drugs: mitigates adverse effects of agents such as pemetrexed.
• Treatment of folate deficiency: replenishes reduced folate stores in patients with inadequate dietary intake or malabsorption.

• Folinic Acid provides a reduced form of folic acid that bypasses the dihydrofolate reductase step, directly entering the folate cycle. This restores the synthesis of thymidine and purine nucleotides and supports methylation reactions, thereby counteracting the inhibition caused by antifolate agents and correcting folate deficiency at the cellular level.

Lederfolin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea
• Vomiting
• Diarrhea
• Mild rash or skin erythema
• Headache
• Transient fever

Serious or Rare Side Effects

• Anaphylactic or severe allergic reactions
• Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Hepatotoxicity with elevated liver enzymes
• Pancytopenia or severe bone‑marrow suppression
• Acute renal failure in predisposed patients

Before initiating Lederfolin, clinicians should consider several safety measures.

• Renal function assessment: adjust dosing in patients with impaired clearance.
• Hepatic monitoring: observe liver enzymes during prolonged therapy.
• Concomitant methotrexate: ensure appropriate timing to avoid antagonism.
• Known hypersensitivity: avoid use in patients with documented folinic acid allergy.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lederfolin may interact with several medications that affect folate pathways or renal clearance.

Major Interactions (Avoid)

• High‑dose methotrexate: concurrent use without proper scheduling can reduce rescue efficacy.
• Pemetrexed: may diminish antifolate activity, requiring dose adjustment.
• Trimethoprim‑sulfamethoxazole: can increase risk of folate depletion.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal elimination of folinic acid.
• Proton‑pump inhibitors: potential reduction in oral absorption.
• Phenytoin and other enzyme‑inducing antiepileptics: may increase folinic acid metabolism.
• Vitamin B12 deficiency: concurrent supplementation may be needed for optimal effect.